HCPCS Level II
Q5135
Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Codes near Q5135
These sit next to Q5135 in the CMS Level II file. All Q codes
- Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5131Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
- Q5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5134Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
- Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
- Q5137Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
- Q5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
- Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
- Q5140Injection, adalimumab-fkjp, biosimilar, 1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 65219-0584-01 | Tyenne | FreseniUS Kabi USA, LLC | 162 |
| 65219-0586-04 | Tyenne | FreseniUS Kabi USA, LLC | 162 |
| 65219-0590-04 | Tyenne | FreseniUS Kabi USA, LLC | 80 |
| 65219-0592-10 | Tyenne | FreseniUS Kabi USA, LLC | 200 |
| 65219-0594-20 | Tyenne | FreseniUS Kabi USA, LLC | 400 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.